机译:遇到的过度表达是一种新的预测标志,用于抗抗EGFR治疗野生型KRAS的转移性结肠直肠癌
Department of Surgery Kyorin University School of Medicine 6-20-2 Shinkawa Mitaka Tokyo 181;
Department of Laboratory Medicine Kyorin University School of Medicine Tokyo Japan;
Department of Surgery Kyorin University School of Medicine 6-20-2 Shinkawa Mitaka Tokyo 181;
Department of Laboratory Medicine Kyorin University School of Medicine Tokyo Japan;
Department of Pathology Kyorin University School of Medicine Tokyo Japan;
Department of Medical Oncology Kyorin University School of Medicine Tokyo Japan;
Department of Laboratory Medicine Kyorin University School of Medicine Tokyo Japan;
Department of Surgery Kyorin University School of Medicine 6-20-2 Shinkawa Mitaka Tokyo 181;
Anti-EGFR therapy; BRAF; Colorectal cancer; MET; PIK3CA; PTEN;
机译:MET的过表达是野生型KRAS转移性结直肠癌抗EGFR治疗的新预测指标
机译:BRAF,PI3K,PTEN,EGFR拷贝数,双调蛋白和上调蛋白状态在KRAS密码子12野生型转移性大肠癌接受一线化疗联合抗EGFR治疗的患者中的预后价值
机译:MicroRNA谱分析预测抗EGFR治疗的化学型难治性转移性结直肠癌患者的野生型KRAS和BRAF生存率
机译:使用无标记微流体技术分离转移性结肠直肠癌患者的循环肿瘤细胞进行募准和检测KRA,BRAF,PIK3CA突变
机译:新型结肠直肠癌促进转移性疾病治疗的疗效
机译:MET的过表达是野生型KRAS转移性结直肠癌抗EGFR治疗的新预测指标
机译:MET的过表达是野生型KRAS转移性结直肠癌抗EGFR治疗的新预测指标